Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 10/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3335635 | 0.88 | TPSAB1 (0.41) | CMA1F11 | |
| SCHEMBL3338358 | 0.86 | CMA1 (0.40) | CMA1 | |
| SCHEMBL3338244 | 0.80 | CMA1 (0.39) | CMA1F11 | |
| SCHEMBL3330783 | 0.79 | TPSAB1 (0.39) | CMA1F11 | |
| SCHEMBL3334212 | 0.78 | CMA1 (0.38) | CMA1F11CCR5 | |
| SCHEMBL3330810 | 0.78 | ATM (0.41) | CMA1 | |
| Trifluoroacetic Acid SCHEMBL3339731 | 0.71 | F11 (0.59) | F11 | |
| SCHEMBL3336687 | 0.71 | TPSAB1 (0.48) | CMA1 | |
| SCHEMBL3333854 | 0.71 | TPSAB1 (0.48) | CMA1 | |
| SCHEMBL3339780 | 0.71 | TPSAB1 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7501404-B2 | Substituted azetidinones | DAIMED (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | CMA1 12/4885F11 17/4885CCR5 1128/4885 |
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | CMA1 12/4885F11 17/4885CCR5 1128/4885 |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | CMA1 12/4885F11 17/4885CCR5 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.